Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)
Έτος δημοσίευσης:
2021
Συγγραφείς:
Hájek, R.
Minarík, J.
Straub, J.
Pour, L.
Jungova, A.
Berdeja, J.G.
Boccadoro, M.
Brozova, L.
Spencer, A.
Van Rhee, F.
Vela-Ojeda, J.
Thompson, M.A.
Abonour, R.
Chari, A.
Cook, G.
Costello, C.L.
Davies, F.E.
Hungria, V.T.M.
Lee, H.C.
Leleu, X.
Puig, N.
Rifkin, R.M.
Terpos, E.
Usmani, S.Z.
Weisel, K.C.
Zonder, J.A.
Barinová, M.
Kuhn, M.
Šilar, J.
Cápková, L.
Galvez, K.
Lu, J.
Elliott, J.
Stull, D.M.
Ren, K.
Maisnar, V.
Minarík, J.
Straub, J.
Pour, L.
Jungova, A.
Berdeja, J.G.
Boccadoro, M.
Brozova, L.
Spencer, A.
Van Rhee, F.
Vela-Ojeda, J.
Thompson, M.A.
Abonour, R.
Chari, A.
Cook, G.
Costello, C.L.
Davies, F.E.
Hungria, V.T.M.
Lee, H.C.
Leleu, X.
Puig, N.
Rifkin, R.M.
Terpos, E.
Usmani, S.Z.
Weisel, K.C.
Zonder, J.A.
Barinová, M.
Kuhn, M.
Šilar, J.
Cápková, L.
Galvez, K.
Lu, J.
Elliott, J.
Stull, D.M.
Ren, K.
Maisnar, V.
Περιοδικό:
Future Oncology
Εκδότης:
Future Medicine Ltd
Τόμος:
17
Αριθμός / τεύχος:
19
Σελίδες:
2499-2512
Λέξεις-κλειδιά:
dexamethasone; ixazomib; lenalidomide; antineoplastic agent; boron derivative; dexamethasone; glycine; ixazomib; lenalidomide, adult; aged; Article; cancer recurrence; clinical outcome; clinical practice; controlled study; data analysis; data integration; diarrhea; drug dose reduction; drug efficacy; drug response; drug safety; drug withdrawal; fatigue; female; follow up; human; infection; major clinical study; male; middle aged; multiple myeloma; neuropathy; neutropenia; observational study; overall response rate; progression free survival; thrombocytopenia; time to treatment; clinical trial; drug resistance; mortality; multicenter study; multiple myeloma; pathology; prospective study; tumor recurrence; very elderly, Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies
Επίσημο URL (Εκδότης):
DOI:
10.2217/fon-2020-1225
Μόνιμη διεύθυνση:
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.
